However, there are noteworthy differences between these previously mentioned studies and our study in determining tau status (CSF vs. PET), cognitive outcome measure used (single test, composite score, or computerized test) and design of the study (cross-sectional cognitive performance vs. longitudinal cognitive decline). This evidence concerns the gene MAPT and Mental deterioration.